| 5.99 0.02 (0.34%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.32 | 1-year : | 7.86 |
| Resists | First : | 6.27 | Second : | 6.73 |
| Pivot price | 6.04  |
|||
| Supports | First : | 5.53 | Second : | 4.6 |
| MAs | MA(5) : | 5.91  |
MA(20) : | 6.07 |
| MA(100) : | 5.57 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.6 |
D(3) : | 27.3 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 7.55 | Low : | 2.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AQST ] has closed above bottom band by 45.0%. Bollinger Bands are 22.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.06 - 6.08 | 6.08 - 6.11 |
| Low: | 5.77 - 5.8 | 5.8 - 5.83 |
| Close: | 5.95 - 5.99 | 5.99 - 6.03 |
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Sun, 21 Dec 2025
Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week - Sahm
Mon, 17 Nov 2025
Aquestive Therapeutics (AQST) Price Target Increased by 14.80% to 10.51 - Nasdaq
Thu, 13 Nov 2025
Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec” - Yahoo Finance
Sat, 08 Nov 2025
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 - Yahoo Finance
Wed, 05 Nov 2025
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Wed, 05 Nov 2025
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 122 (M) |
| Shares Float | 111 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 56.9 (%) |
| Shares Short | 19,830 (K) |
| Shares Short P.Month | 14,740 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.03 |
| Profit Margin | -159 % |
| Operating Margin | -89.7 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 0.35 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -8.56 |
| PEG Ratio | 0 |
| Price to Book value | -199.67 |
| Price to Sales | 16.83 |
| Price to Cash Flow | -14.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|